Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 6/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24553835 | 1.00 | MAPK14 (0.46) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL24554183 | 0.99 | MAPK14 (0.44) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL29683088 | 0.99 | MAPK14 (0.44) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL24553870 | 0.90 | MAPK14 (0.47) | MAPK14CSNK1DGSK3BDYRK1AALDH1A1 | |
| SCHEMBL29683024 | 0.89 | MAPK14 (0.41) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL24553845 | 0.89 | MAPK14 (0.41) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL29682954 | 0.89 | MAPK14 (0.43) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL24553781 | 0.89 | MAPK14 (0.46) | MAPK14CSNK1DGSK3BDYRK1AALDH1A1 | |
| SCHEMBL24553878 | 0.89 | MAPK14 (0.43) | MAPK14CSNK1DMAPK8MAPK10CSNK1E | |
| SCHEMBL24553851 | 0.88 | MAPK14 (0.55) | MAPK14CSNK1DGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2022127756-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | MAPK14 219/4885CSNK1D 12/4885MAPK8 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.